The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: Gullain-Barre Syndrome following therapy with an immune checkpoint inhibitor
Parameters:
(1) signs and symptoms
(2) activities of daily living (ADL)
|
Signs and Symptoms
|
Activities of Daily Living
|
Grade
|
|
moderate
|
interference with ADL
|
G2
|
|
severe
|
limited self-care
|
G3/G4
|
|
weakness limiting walking, any dysphagia, facial weakness, and/or respiratory muscle weakness
|
NA
|
G3/G4
|
|
rapidly progressive
|
NA
|
G3/G4
|
where:
• There is no Grade 1.
• Mild symptoms are ungraded.
The diagnosis requires exclusion of other causes for the neurologic findings.
